Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 12.98 USD -5.39% Market Closed
Market Cap: 2.8B USD

Wall Street
Price Targets

OCUL Price Targets Summary
Ocular Therapeutix Inc

Wall Street analysts forecast OCUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCUL is 22.78 USD with a low forecast of 18.18 USD and a high forecast of 32.55 USD.

Lowest
Price Target
18.18 USD
40% Upside
Average
Price Target
22.78 USD
76% Upside
Highest
Price Target
32.55 USD
151% Upside
Ocular Therapeutix Inc Competitors:
Price Targets
VETO
Vetoquinol SA
15% Upside
603520
Zhejiang Starry Pharmaceutical Co Ltd
53% Upside
195940
HK Inno.N Corp
25% Upside
4521
Kaken Pharmaceutical Co Ltd
14% Upside
1093
CSPC Pharmaceutical Group Ltd
25% Upside
EAH
ECO Animal Health Group PLC
101% Upside
069620
Daewoong Pharma
17% Upside

Revenue
Forecast

Revenue Estimate
Ocular Therapeutix Inc

The compound annual growth rate of Ocular Therapeutix Inc's revenue for the next 4 years is 37%.

N/A
Past Growth
37%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Ocular Therapeutix Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Ocular Therapeutix Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-82%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OCUL's stock price target?
Price Target
22.78 USD

According to Wall Street analysts, the average 1-year price target for OCUL is 22.78 USD with a low forecast of 18.18 USD and a high forecast of 32.55 USD.

What is Ocular Therapeutix Inc's Revenue forecast?
Projected CAGR
37%

The compound annual growth rate of Ocular Therapeutix Inc's revenue for the next 4 years is 37%.

Back to Top